Skip to content

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION, DIABETES AND CHRONIC KIDNEY DISEASE, EUROASPIRE VI

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION, DIABETES AND CHRONIC KIDNEY DISEASE, EUROASPIRE VI - EUROASPIRE VI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57093
Enrollment
800
Registered
2024-05-22
Start date
2025-01-07
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease ischemic heart disease heart disease

Interventions

N.v.t.

Sponsors

European Society of Cardiology
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Patients having signed an informed Consent • Patients aged from 18 years old at the time of identification • At least six and at most 24 months elapsed between the index event (the recruiting diagnostic or treatment criteria below) and the date of interview • Patients meeting the recruiting diagnostic or treatment criteria: - Coronary patients: Acute coronary events (acute coronary syndrome {STEMI or NSTEMI}, unstable angina) or an emergency or elective revascularisation for coronary artery disease (CABG, PCI)

Exclusion criteria

Exclusion criteria: • Patients living outside defined geographical areas • Patients admitted to hospital from outside the geographical area or under the care of cardiologists in hospitals that do not participate in EUROASPIRE VI

Design outcomes

Primary

MeasureTime frame
To evaluate the proportion of patients achieving European lifestyle, risk factors and therapeutic targets for cardiovascular disease prevention.

Secondary

MeasureTime frame
N.v.t.

Countries

Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Slovenia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Uzbekistan

Contacts

Public ContactM.J.G. Leening

Erasmus MC, Universitair Medisch Centrum Rotterdam

m.leening@erasmusmc.nl0107040704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026